オカザキ　ケン   OKAZAKI Ken   岡崎　賢    所属   医学部 医学科（東京女子医科大学病院）    職種   教授・基幹分野長
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Radiological evaluation of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept or JAK inhibitors for 1 year.
掲載誌名	正式名：Respiratory investigation 略　 称：Respir Investig ISSNコード：22125353/22125345
掲載区分	国外
巻・号・頁	61(3),pp.359-363
著者・共著者	Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ken Okazaki
担当区分	最終著者
発行年月	2023/05
概要	BACKGROUND:We evaluated the radiological deterioration of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with abatacept (ABT) or Janus-kinase inhibitors (JAKi) for 1 year.METHODS:This study enrolled 84 patients with RA who had started treatment with ABT (48 patients) or JAKi (36 patients) between 2017 and 2020. All patients underwent chest CT before administration and at 1 year post-treatment.RESULTS:In all patients, the rate of deterioration of ILD in ABT and JAKi was 4.2% and 5.6%, respectively (p = 0.847). In the patients with pre-existing ILD, the rates of deterioration of ILD in the ABT and JAKi groups were 10.5% and 18.2%, respectively (p = 0.611). Meanwhile, newly developed ILD did not occur in the two groups without pre-existing ILD.CONCLUSION:The present study demonstrated that the safety of pulmonary toxicity with ABT and JAKi treatments was similar in patients with RA. JAKi may be a potentially acceptable treatment option for patients with RA.
DOI	10.1016/j.resinv.2023.02.007
PMID	37031622